文献速递妇科

中国首个全国性妇科肿瘤真实世界研究与患者管理平台:一项回顾性研究

The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.
PubMed 文献 · BJOG · 2022-01-01

该研究建立NUWA平台,整合中国13家三甲医院11456例卵巢癌患者的91345份电子病历,构建以患者为中心的数据池。结果显示2017至2018年BRCA突变检测率增加约六倍,2018年9月奥拉帕利在中国获批后PARP抑制剂一线及二线治疗使用率呈类似趋势。

要点

  • NUWA平台整合13家三甲医院11456例卵巢癌患者数据,构建以患者为中心的数据池。
  • 2017至2018年BRCA突变检测率增加约六倍。
  • 2018年9月奥拉帕利获批后PARP抑制剂一线及二线治疗使用率呈类似上升趋势。

核心结论

  • NUWA平台在促进临床研究、支持药物开发、监管审评和医疗决策方面具有巨大潜力。

研究设计与样本

  • 回顾性研究,基于全国妇科肿瘤真实世界研究与患者管理平台(NUWA平台)开展。
  • 截至2021年12月7日,中国13家三甲医院参与NUWA平台。
  • 收集11456例卵巢癌患者的数据,使用91345份电子病历进行处理。

主要发现

  • 3504例(30.59%)患者由独立患者管理中心进行随访。
  • 2017年至2018年间,接受乳腺癌基因(BRCA)突变检测的患者百分比增加约六倍。
  • 2018年9月奥拉帕利在中国获批临床使用后,聚(ADP-核糖)聚合酶抑制剂作为一线治疗和二线治疗的给药率呈现类似趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To produce high-quality, real-world evidence for oncologists by collating scattered gynaecologic oncology (GO) medical records in China. DESIGN: Retrospective study. SETTING: The National Union of Real-world Gynaecological Oncology Research and Patient Management Platform (NUWA platform). SAMPLE: Patient-centred data pool. METHODS: The NUWA platform integrated inpatient/outpatient clinical, gene and follow-up data. Data of 11 456 patients with ovarian cancer (OC) were collected and processed using 91 345 electronic medical records. Structured and unstructured data were de-identified and re-collated into a patient-centred data pool using a predefined GO data model by technology-aided abstraction. MAIN OUTCOME MEASURES: Recent treatment pattern shifts towards precision medicine for OC in China. RESULTS: Thirteen first-tier hospitals across China participated in the NUWA platform up to 7 December 2021. In total, 3504 (30.59%) patients were followed up by a stand-alone patient management centre. The percentage of patients undergoing breast cancer gene (BRCA) mutation tests increased by approximately six-fold between 2017 and 2018. A similar trend was observed in the administration rate of poly(ADP-ribose) polymerase inhibitors as first-line treatment and second-line treatment after September 2018, when olaparib was approved for clinical use in China. CONCLUSION: The NUWA platform has great potential to facilitate clinical studies and support drug development, regulatory reviews and healthcare decision-making.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Zeng S, Chi J, Liu J, et al. The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study. BJOG. 2022. PMID: 36485066. doi:10.1111/1471-0528.17328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。